Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : How To Write Covered Calls - An Ongoing Real Case Study! -- Ignore unavailable to you. Want to Upgrade?

To: sailor who wrote (6019)	12/3/1997 7:54:00 PM
From: Herm	Respond to of 14162

Well Sailor, That does happen to all of us from time to time! Dec. 35s seems like a real long shot from the current VVUS price level of $22+. And the VVUS volume has been peanuts as you indicated! Not even option bids for some strike prices! I watched ticks where the VVUS MMs allowed 200 - 300 shares trades to knock down VVUS a 1/2 point to make the sale. At the end of the day there is a stream of 500 shares trades to depress the stock price. Well, things might get better with a more experienced CEO! Wednesday December 3, 7:36 am Eastern Time Company Press Release VIVUS Elects Michael I. Levitt Vice President, Operations MENLO PARK, Calif.--(BW HealthWire)--Dec. 3, 1997--VIVUS, Inc (NASDAQ:VVUS - news) today announced the appointment of Michael I. Levitt to the position of vice president, operations. Levitt, who has 21 years of experience in the pharmaceutical industry, served most recently as vice president of global Collagen operations and general manager of Lipomatrix, Inc., a division of Collagen Corporation [Nasdaq:CGEN - news]. In his three years with Collagen, Levitt was responsible for global manufacturing and distribution. During 1997, Levitt assumed the added responsibility for the manufacturing and R&D facilities of the Lipomatrix breast implant facilities in Neuchatel, Switzerland. Prior to his tenure at Collagen, Levitt held various positions at Eli Lilly & Co., from 1976 to 1994, most recently as director of production operations. Levitt holds a B.S. degree in pharmacy from the University of Buffalo. ''Our challenge in 1998 will be to continue our current level of production in our existing facility while bringing our new manufacturing facility in New Jersey on line as well as completing construction of a significant portion of our facility in Ireland. Mike's broad experience in pharmaceutical manufacturing complete with his general management skills are valuable assets for VIVUS,'' said Leland F. Wilson, president and CEO.